European Companies Search Engine
EU funding (€750,000): 190138295 - Down-Autonomy - Lctb-21: a Dyrk1A Protein Kinase Inhibitor for Treatment of Cognitive Decline in Down Syndrome. Fts1 Jun 2022 Financial Transparency System
Overview
Text
Project
| Subject of Grant or Contract | 190138295 - DOWN-AUTONOMY - LCTB-21: A DYRK1A PROTEIN KINASE INHIBITOR FOR TREATMENT OF COGNITIVE DECLINE IN DOWN SYNDROME. |
| Responsible Department | EISMEA - European Innovation Council and SMEs Executive Agency |
| Programme Name | 1.0.11 - Horizon Europe |
| Type of Contract* | Action Grant |
| Reference of the Legal Commitment (LC) | JAG.1114832 |
| Management Type | Direct management |
| Geographical Zone | - |
| Budget | BGUE |
| Action Location | - |
| Commitment Total Amount (EUR) (A+B) | 750,000.00 |
| Project end Date | 30/06/2026 |
| Commitment Contracted Amount (EUR) (A) | 750,000.00 |
| Benefiting Country | France 100% |
| Budget Line Name | European Innovation Council |
| Funding Type | Grant |
| Additional/Reduced Amount (EUR) (B) | 0.00 |
| Year | 2022 |
| Source of (Estimated) Detailed Amount | The total amount of the commitment was attributed to a single beneficiary. |
| Reference (Budget) | JAG.1114832.2 |
| Commitment Consumed Amount (EUR) | 250,000.00 |
| Budget Line Number | 01 02 03 01 |
| Project Start Date | 01/06/2022 |
| Expense Type | Operational |
Beneficiaries
| Coordinator | No |
| Address | LIEUDIT PRESQUILE DE PERHARIDY BATI |
| Beneficiary’s Contracted Amount (EUR) | 750,000.00 |
| Beneficiary’s Estimated Contracted Amount (EUR) | 750,000.00 |
| Postal Code | 29680 |
| Beneficiary Country | France |
| Beneficiary’s Estimated Consumed Amount (EUR) | 250,000.00 |
| VAT Number of Beneficiary | FR34850455429 |
| Beneficiary Group Code | LE05 |
| Not-for-Profit Organisation (Nfpo) | No |
| Beneficiary Type | Private Companies |
| Name of Beneficiary | PERHA PHARMACEUTICALS |
| NUTS2 | Bretagne |
| City | ROSCOFF |
| Non-Governmental Organisation (NGO) | No |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Perha Pharmaceuticals SAS, Roscoff, France.
The visualizations for "Perha Pharmaceuticals - EU funding (€750,000): 190138295 - Down-Autonomy - Lctb-21: a Dyrk1A Protein Kinase Inhibitor for Treatment of Cognitive Decline in Down Syndrome."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
